Expertise in
25
conditions

Dr. Anastasios Raptis

Hematology
Mario Lemieux Center For Blood Cancers
5115 Centre Ave Fl 4, 
Pittsburgh, PA 
Expertise in
25
conditions
Mario Lemieux Center For Blood Cancers
5115 Centre Ave Fl 4, 
Pittsburgh, PA 

Overview

Anastasios Raptis is a Hematologist practicing medicine in Pittsburgh, Pennsylvania.

Dr. Raptis is highly rated in 25 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Acute Myeloid Leukemia (AML), Non-Hodgkin Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 31 peer reviewed articles and participating in 3 clinical trials.

Specialties

Hematology

Licenses

Internal Medicine in PA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Gateway Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Geisinger
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
PA Health and Wellness
  • HMO
  • MANAGED MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

Mario Lemieux Center for Blood Cancers
5115 Centre Ave Fl 4, Pittsburgh, PA 15232

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Single Arm, Open-Label, Phase 2 Study of Melflufen in Combination With Dexamethasone in Patients With Relapsed Refractory Multiple Myeloma Who Are Refractory to Pomalidomide and/or an Anti-CD38 Monoclonal Antibody
A Single Arm, Open-Label, Phase 2 Study of Melflufen in Combination With Dexamethasone in Patients With Relapsed Refractory Multiple Myeloma Who Are Refractory to Pomalidomide and/or an Anti-CD38 Monoclonal Antibody
Enrollment Status: Completed
Publish Date: November 22, 2022
Intervention Type: Drug
Study Drugs: Melphalan Flufenamide (Melflufen), Dexamethasone
Study Phase: Phase 2
A Phase 1/2, Dose Escalation, Safety and Tolerability Study of BION-1301 in Adults With Relapsed or Refractory Multiple Myeloma
A Phase 1/2, Dose Escalation, Safety and Tolerability Study of BION-1301 in Adults With Relapsed or Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: April 01, 2021
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source
Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source
Enrollment Status: Completed
Publish Date: October 15, 2019
Intervention Type: Drug, Other, Radiation
Study Phase: Phase 1
View 2 Less Clinical Trials

31 Total Publications

A phase II study of post-remission therapy with pembrolizumab in older patients with acute myeloid leukemia.
A phase II study of post-remission therapy with pembrolizumab in older patients with acute myeloid leukemia.
Journal: Haematologica
Published: February 18, 2024
Similar Doctors
Expertise in
9
conditions
Expertise in
9
conditions
Referral may be required
Before you request

Classical Hematology

3601 Fifth Ave, Falk Building, 3rd Floor, 
Pittsburgh, PA 
 (1.4 miles away)
412-586-9875
Languages Spoken:
English, Italian, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Enrico M. Novelli, MD, is a classical (benign) hematologist, the Chief of the Section of Benign Hematology, and the medical director of the UPMC Adult Sickle Cell Disease Program. Board-certified in hematology, Dr. Novelli received his medical degree from the University of Milan, Italy. He completed his residency in internal medicine and fellowship in hematology-oncology at UPMC. Dr. Novelli specializes in sickle cell anemia and hemoglobinopathies. Dr. Novelli is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Sickle Cell Disease, Congenital Hemolytic Anemia, Hemolytic Anemia, and Hemoglobinopathy. Dr. Novelli is board certified in American Board Of Internal Medicine. Dr. Novelli is currently accepting new patients.

Expertise in
14
conditions
Expertise in
14
conditions
Referral may be required
Before you request

Classical Hematology

3601 Fifth Ave, Falk Building, 3rd Floor, 
Pittsburgh, PA 
 (1.4 miles away)
412-586-9875
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Craig Seaman is a Hematologist practicing medicine in Pittsburgh, Pennsylvania. Dr. Seaman is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Von Willebrand Disease (VWD), Hemophilia A, Blood Clots, and Hemophilic Arthropathy. Dr. Seaman is board certified in American Board Of Internal Medicine. Dr. Seaman is currently accepting new patients.

Expertise in
38
conditions
Expertise in
38
conditions
Referral may be required

Univ. Of Pittsburgh Cancer Institute Cancer Services

5115 Centre Ave Fl 3, 
Pittsburgh, PA 
 (0.1 miles away)
412-235-1020
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Mounzer Agha is a Hematologist practicing medicine in Pittsburgh, Pennsylvania. Dr. Agha is highly rated in 38 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Smoldering Multiple Myeloma, Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Agha is currently accepting new patients.

Frequently Asked Questions about Dr. Anastasios Raptis

How do I make an appointment with Dr. Anastasios Raptis?

You can book an appointment with Dr. Anastasios Raptis by calling their office at 412-864-6600. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Anastasios Raptis a top-rated expert for Multiple Myeloma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Anastasios Raptis is classified as an Distinguished expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Anastasios Raptis specialize in?

While Dr. Anastasios Raptis is a Hematology, they have specific expertise in Multiple Myeloma, Acute Myeloid Leukemia (AML), and Non-Hodgkin Lymphoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Anastasios Raptis participate in research or clinical trials?

Yes. Dr. Anastasios Raptis has published 31 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Dr. Anastasios Raptis's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Anastasios Raptis accept my insurance?

Dr. Anastasios Raptis accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 412-864-6600 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Raptis's expertise for a condition
ConditionClose
    View All 19 Advanced Conditions
    View All 36 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile